Latest studies
- RecruitingPHASE2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment called ABBV-142 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to check if the new drug is safe, what side effects it might cause, and if it helps improve the condition compared to a dummy drug.
Idiopathic Pulmonary FibrosisPortugal - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerPortugal - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
Small Cell Lung CarcinomaPortugal - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisPortugal - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Portugal - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
Non-small Cell Lung CancerPortugal - Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
Breast CancerPortugal - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisPortugal - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia APortugal - Active not recruitingPHASE3
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
This study looks at the long-term safety of a new medicine, PTC923, for people with Phenylketonuria (PKU). It also checks if the medicine helps people eat more varied foods by seeing if their usual diet and protein intake change over time.
PhenylketonuriaPortugal - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaPortugal - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Portugal - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
Immunoglobulin A NephropathyPortugal - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionPortugal - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaPortugal - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
Non-Small Cell Lung CancerPortugal - Active not recruitingPHASE3
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This study looks at new treatments for Mantle Cell Lymphoma in adults who can't have a stem cell transplant. It compares two drug combinations to see which works better and is safer.
Mantle Cell Lymphoma; Non-Hodgkin LymphomaPortugal - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseasePortugal - Active not recruitingPHASE3
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study is looking at two medicines, Depemokimab and Mepolizumab, for adults with a rare condition called EGPA. We want to see how well they work and if they are safe when patients are already having standard treatment.
Eosinophilic Granulomatosis With PolyangiitisPortugal - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
Neoplasms, LungPortugal - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerPortugal - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseasePortugal - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
Breast CancerPortugal - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Portugal - Active not recruitingPHASE3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
This study is testing a new drug called frexalimab for people with a type of multiple sclerosis (MS) called non-relapsing secondary progressive MS (nrSPMS). Researchers want to see if it can slow down MS progression and if it's safe. It's compared to a dummy drug (placebo).
Multiple SclerosisPortugal - Active not recruitingPHASE3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is looking at a new medicine called vutrisiran for people with a heart condition called transthyretin amyloidosis (ATTR) cardiomyopathy. It aims to see if the medicine can help improve the condition and if it's safe compared to a dummy treatment.
Transthyretin Amyloidosis (ATTR) With CardiomyopathyPortugal - RecruitingPHASE3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart, against the usual treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It's for adults already receiving IVIg to see if riliprubart works safely and effectively to manage their condition.
Chronic Inflammatory Demyelinating PolyneuropathyPortugal - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Portugal - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerPortugal - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerPortugal - Active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
Relapsed or Refractory Multiple MyelomaPortugal - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerPortugal - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
Colonic NeoplasmsNeoplasms, ColonPortugal - Enrolling by invitationPHASE3
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study looks at the long-term safety and effects of a new drug called litifilimab for adults with certain types of lupus affecting the skin. It's for people who were in an earlier study and whose lupus didn't improve with usual treatments.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusPortugal - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerPortugal - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
HER2 Positive Breast CancerPortugal - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerPortugal - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenPortugal - RecruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
Multiple MyelomaPortugal - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsPortugal - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
This study compares two medicines, crovalimab and eculizumab, for a rare blood condition called PNH. It's for people who haven't tried these types of medicines before, checking if crovalimab works as well and is as safe as eculizumab.
Paroxysmal Nocturnal HemoglobinuriaPortugal - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseasePortugal - Active not recruitingPHASE3
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
This study is testing a new medicine, Belumosudil, alongside standard steroids for people aged 12 and over newly diagnosed with chronic Graft-versus-Host Disease (cGVHD). We want to see if this combination works better to manage the condition.
Chronic Graft Versus Host DiseasePortugal - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
This study is looking into a new treatment called Dazodalibep for Sjögren's Syndrome. It wants to see if the treatment helps reduce symptoms and if it's safe for people whose Sjögren's is causing moderate to severe problems in their body.
Sjogren's SyndromePortugal - RecruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
OverweightObesityPortugal - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsPortugal - Active not recruitingPHASE3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
This study is looking into a new medicine called ziltivekimab for people with heart failure and inflammation. It compares ziltivekimab to a dummy medicine (placebo) to see if it can help. The treatment you receive is chosen by chance, and the study will last up to 1 year and 4 months.
Heart FailureSystemic InflammationPortugal - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
Diffuse Large B-Cell LymphomaPortugal - RecruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
Alopecia AreataPortugal - Active not recruitingPHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is looking at a new combination of medicines, Dato-DXd and pembrolizumab, for advanced lung cancer. It compares this combination to pembrolizumab alone to see if it's more effective and safe for people whose cancer hasn't spread and who haven't had other treatments yet.
Metastatic Non Small Cell Lung CancerPortugal